Background
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) remain a cornerstone of antiretroviral therapy (ART). Depulfavirine (DPV), the active metabolite of the prodrug elsulfavirine, is a novel NNRTI with favorable pharmacological properties currently under clinical development. While its antiviral potency has been demonstrated, the structural basis of RT inhibition, its biochemical resistance profile, and how DPV behaves in drug combinations remain unknown. Understanding these features is essential for optimizing ART regimens and guiding the development of next-generation NNRTIs.
Methods
We determined a 2.4 Å X-ray crystal structure of HIV-1 reverse transcriptase (RT) in complex with DPV (PDB: 7TAZ). Structural analyses were performed to define key interactions and conformational changes within the non-nucleoside inhibitor binding pocket (NNIBP), and findings were compared with other NNRTIs. Biochemical primer extension assays using recombinant RT variants containing clinically relevant NNRTI-resistance mutations were used to assess susceptibility. Cell-based antiviral assays evaluated drug–drug interactions between DPV and long-acting antivirals, with outcomes analyzed using standard synergy models.
Results
The crystal structure revealed that the tricyclic ring system of DPV adopts an extended conformation within the NNIBP. Resistance profiling showed that DPV retained activity against several first- and second-generation NNRTI resistance mutations, with reduced susceptibility observed for F227C and the V106A/F227C double mutant, consistent with cell-based studies. Synergy analyses demonstrated additive interactions between DPV and multiple partners, including the long-acting agents islatravir (ISL), cabotegravir (CAB), and lenacapavir (LEN), as well as with tenofovir disoproxil fumarate (TDF).
Conclusions
DPV engages the NNRTI binding pocket through an extended binding mode that stabilizes interactions across key residues in the NNIBP. This binding pattern aligns with its broad antiviral activity and observed resistance profile. Combined with biochemical and synergy analyses, these findings show that DPV maintains activity across resistant RT variants and supports its potential role in both long-acting and combination ART regimens. These results provide mechanistic insight into NNRTI inhibition and inform strategies for optimizing antiretroviral therapy.